Cargando…
Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder
AIM: Atomoxetine (ATX) is a non‐central stimulant and a standard treatment for adult attention‐deficit/hyperactivity disorder (ADHD). The long‐term efficacy of Atomoxetine is about 40% at 6 months. The variability in efficacy between individuals is thought to be related to patient‐specific factors,...
Autores principales: | Nagai, Tsutomu, Kurihara, Tatsuya, Koya, Hiroaki, Nakano, Yukako, Sugisawa, Satoru, Sambe, Takehiko, Kishimoto, Keiko, Kogo, Mari, Ota, Haruhisa, Iwanami, Akira, Uchida, Naoki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515700/ https://www.ncbi.nlm.nih.gov/pubmed/35485452 http://dx.doi.org/10.1002/npr2.12253 |
Ejemplares similares
-
Risk factors for readmission in schizophrenia treated with combined psychoeducation and standard therapy
por: Sugisawa, Satoru, et al.
Publicado: (2022) -
Differential therapeutic effects of atomoxetine and methylphenidate in childhood attention deficit/hyperactivity disorder as measured by near-infrared spectroscopy
por: Nakanishi, Yoko, et al.
Publicado: (2017) -
Effect of Atomoxetine on Hyperactivity in an Animal Model of Attention-Deficit/Hyperactivity Disorder (ADHD)
por: Moon, Su Jin, et al.
Publicado: (2014) -
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
por: Price, Maxwell Z., et al.
Publicado: (2023) -
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
por: Hammerness, Paul, et al.
Publicado: (2009)